卫生研究

参考文献

[1] 胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要[J].中国循环杂志，2019,34(3):209-220.

[2] ASHJAZADEH N,FATHI M,SHARIAT A.Evaluation of homocysteine level as a risk factor among patients with ischemic stroke and its subtypes[J].Iran J Med Sci,2013,38(3):233-239.

[3] GOPINATH B,FLOOD V M,ROCHTCHINA E,et al.Serum homocysteine and folate but not vitamin B12 are predictors of CHD mortality in older adults[J].Eur J Prev Cardiol,2012,19(6):1420-1429.

[4] CATENA C,COLUSSI G,URL-MICHITSCH M,et al.Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension[J].J Am Soc Hypertens,2015,9(3):167-175.

[5] 杨月欣，葛可佑.中国营养科学全书[M].2版.北京：人民卫生出版社，2019.

[6] ZHANG S,WANG T,WANG H,et al.Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension:a double-blinded,randomized clinical cohort study[J].Medicine,2022,101(3):e28628.

[7] QIN X,SPENCE J D,LI J,et al.Interaction of serum vitamin B12 and folate with MTHFR genotypes on risk of ischemic stroke[J].Neurology,2020,94(11):e1126-e1136.

[8] WANG B,WU H,LI Y,et al.Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering:major effect modifiers[J].Bri J Nutr,2018,120(10):1122-1130.

[9] ZHAO M,WANG X,HE M,et al.Homocysteine and stroke risk modifying effect of methylenetetrahydrofolate reductase C677T polymorphism and folic acid intervention[J].Stroke,2017,48(5):1183-1190.

[10] HUO Y,LI J,QIN X,et al.Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China:the CSPPT randomized clinical trial[J].JAMA,2015,313(13):1325-1335.

[11] CHMURZYNSKA A,MALINOWSKA A M,TWARDOWSKA-RAJEWSKA J,et al.Elderly women:homocysteine reduction by short-term folic acid supplementation resulting in increased glucose concentrations and affecting lipid metabolism (C677T MTHFR polymorphism) [J].Nutrition,2013,29(6):841-844.

[12] QIN X H,LI J,CUI Y,et al.MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults[J].Nutr J,2012,11:2.

[13] MAZZA A,MONTEMURRO D,L’ERARIO R,et al.Could genetic analysis be useful in reducing cerebrovascular risk in hypertensive subjects with hyperhomocysteinemia and patent foramen ovale?A 2-year follow-up study[J].Microvasc Res,2010,80(3):545-548.

[14] WILLIAMS C,KINGWELL B A,BURKE K,et al.Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype[J].Am J Clin Nutr,2005,82(1):26-31.

[15] LIU C S,CHIANG H C,CHEN H W.Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease[J].Nutrition,2004,20(11-12):974-978.

[16] FOHR I P,PRINZ-LANGENOHL R,BRONSTRUP A,et al.5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women[J].Am J Clin Nutr,2002,75(2):275-282.

[17] MAYER O J,SIMON J,ROSOLOVA H,et al.The effects of folate supplementation on some coagulation parameters and oxidative status surrogates[J].Eur J Clin Pharmacol,2002,58(1):1-5.

[18] MAYER O,FILIPOVSKY J,HROMADKA M,et al.Treatment of hyperhomocysteinemia with folic acid:effects on homocysteine levels,coagulation status,and oxidative stress markers[J].J Cardiovasc Pharmacol,2002,39(6):851-857.

[19] KRUGER W D,EVANS A A.Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid[J].Mol Genet Metab,2000,70(1):53-60.

[20] 陈萍，陈肖霞，谢利坤，等.小剂量叶酸降低H型高血压患者高同型半胱氨酸及其MTHFR C677T基因多态性的研究[J].中国医药指南，2022,20(18):68-70.

[21] 董文红，褚强强，章车明，等.高血压病人同型半胱氨酸与MTHFR 677 C/T基因多态性相关性研究及不同剂量叶酸干预效果评价[J].蚌埠医学院学报，2022,47(3):334-336.

[22] 王子文.H型高血压患者MTHFR C677T 基因多态性及其对同型半胱氨酸治疗效果影响的研究[D].承德：承德医学院，2022.

[23] 卢晓燕，任钰.不同剂量叶酸对不同MTHFR基因型缺血性脑卒中伴高同型半胱氨酸血症患者同型半胱氨酸水平的影响[J].中国医药导报，2021,18(17):90-94.

[24] 李树刚.H型高血压患者MTHFR基因多态性及按基因分型叶酸治疗的临床效果[J].医疗装备，2021,34(9):96-97.

[25] 贾晓云.马来酸依那普利叶酸片治疗H型高血压患者的效果及其与MTHFR基因多态性的相关性[J].广西医学，2021,43(5):545-548.

[26] 贺慧芬.脑梗死患者MTHFR基因多态性对叶酸治疗高同型半胱氨酸疗效的影响[D].延安：延安大学医学院，2021.

[27] 杨旭光，徐炳欣，赵艳，等.MTHFR C677T基因多态性对稳定性冠心病患者叶酸降低同型半胱氨酸治疗的影响[J].中国循证心血管医学杂志，2020,12(2):179-181.

[28] 居春阳，薛冰，张会丽，等.MTHFRC677T基因多态性对小剂量叶酸降低缺血性卒中患者同型半胱氨酸水平的影响[J].临床医学研究与实践，2020,5(32):63-65.

[29] 张云飞，徐炳欣，赵艳，等.MTHFR C677T基因多态性对H型高血压患者叶酸降低同型半胱氨酸治疗的影响[J].河南医学研究，2020,29(12):2135-2138.

[30] 沈晓红，徐象威，程超婵，等.永康地区H型高血压患者MTHFR基因多态性及按基因分型叶酸治疗疗效观察[J].临床检验杂志，2019,37(6):423-427.

[31] 沈婷婷，汪思阳，张娴，等.H型高血压患者MTHFR基因多态性与缬沙坦联合叶酸片治疗效果的关系[J].临床和实验医学杂志，2019,18(13):1407-1410.

[32] 刘桂宾.硝苯地平控释片联合叶酸片在H型高血压患者中的降压效果及血浆Hcy水平变化分析[D].青岛：青岛大学医学部，2019.

[33] 陈倩倩.MTHFR C677T基因多态性对脑卒中伴高同型半胱氨酸血症叶酸治疗影响的研究[D].合肥：安徽中医药大学，2020.

[34] 田京辉，徐炳欣，赵艳，等.MTHFRC677T基因多态性对叶酸治疗缺血性脑卒中患者高同型半胱氨酸血症的影响[J].中国医院用药评价与分析，2018,18(10):1325-1327.

[35] 刘鹏，钟萍，孙学春，等.H型高血压患者MTHFR基因多态性及叶酸补充对同型半胱氨酸浓度的影响[J].岭南心血管病杂志，2018,24(3):311-313.

[36] 章衍达.MTHFR C677T基因突变对H型高血压患者Hcy水平的影响及小剂量叶酸干预的临川研究[D].南京：南京医科大学，2018.

[37] 刘玥，张欣，侯辰，等.MTHFR基因多态性对不同剂量叶酸治疗高同型半胱氨酸血症的影响[J].中国医学前沿杂志(电子版),2016,8(6):115-118.

[38] 李鹏.老年冠心病患者中MTHFR基因型对叶酸降同型半胱氨酸效果的影响[D].郑州：郑州大学，2014.

[39] 梁毅珊.MTHFR基因多态性与叶酸治疗高血压患者Hcy疗效研究[J].黑龙江医学，2014,38(12):1379-1380.

[40] 吕纯芳，张涛，李丽玲，等.MTHFR基因多态性对药物联合干预H型高血压血浆Hcy动态监测的影响[J].实用预防医学，2013,20(12):1509-1511.

[41] 徐艳龙，张善春，李建平，等.轻中度高血压患者中MTHFR基因多态性对血清叶酸-血浆同型半胱氨酸相关性的影响[J].安徽医科大学学报，2006,41(6):639-643.

[42] 徐炳欣，赵艳，段淑娟，等.亚甲基四氢叶酸还原酶A1298C基因多态性检测在高同型半胱氨酸血症治疗中的价值[J].中华全科医学，2020,18(9):1470-1473.

[43] 陈倩茹.依那普利叶酸片、辛伐他汀药物疗效个体差异的易感基因研究[D].合肥：安徽大学，2012.

[44] STANGER O,HERRMANN W,PIETRZIK,et al.DACH-LIGA homocysteine (German,Austrian and Swiss homocysteine society):consensus paper on the rational clinical use of homocysteine,folic acid and B-vitamins in cardiovascular and thrombotic diseases:guidelines and recommendations[J].Clin Chem Lab Med,2004,42(1):113-116.

[45] HOLMES M V,NEWCOMBE P,HUBACEK J A,et al.Effect modification by population dietary folate on the association between MTHFR genotype,homocysteine,and stroke risk:a meta-analysis of genetic studies and randomised trials[J].Lancet,2011,378(9791):584-594.